QBiotics to participate in the first international symposium dedicated to intratumoural immunotherapy
BRISBANE, 9 June 2026
QBiotics Group Limited (QBiotics) is pleased to announce its participation in and co-sponsorship of the ‘Intratumoural Immunotherapy Symposium 2026’, the first international clinical and scientific meeting dedicated to intratumoural immunotherapy. The event will be hosted by the Gustave Roussy Institute in Paris from 11 to 12 June 2026.
Intratumoural Immunotherapy is one of the emerging and most closely watched areas in oncology and this Symposium will bring together pharmaceutical companies and leading clinicians and researchers in the field.
QBiotics’ participation in this inaugural Symposium builds on our longstanding relationship with Gustave Roussy, one of Europe’s leading cancer centres, and comes at a pivotal time for the company where our primary strategic focus is partnering of our intratumoural drug tigilanol tiglate within the evolving oncology treatment landscape.
— ends —
FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
NOTES FOR EDITORS
ABOUT QBIOTICS
QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. In a Phase II soft tissue sarcoma study the drug delivered an injected tumour Objective Response Rate (ORR) of 80%, with no serious Adverse Events, and translational research validating immunological responses. A Phase II study in head & neck cancer is soon to be reported and impressive safety and efficacy outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I/IIa safety study and efficacy reported for nine different tumour types.
QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human clinical Phase I/IIa study treating Venous Leg Ulcers.
Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of the drug secured for both programmes.
QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complimented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, and translational drug development.
QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.
For more, head to: QBiotics.com or LinkedIn